On June 9th, a message “Japan Internet Red Eye Drops was banned in Canada” was posted on the hot search.
Due to the possible serious side effects of the ingredients, four Japanese eye drops including the Shentian FX and PC and two other eye products were required to be removed from Canada in April, and the e-commerce of these products in China. The platform and the purchasing office can be purchased at will and the sales volume is considerable, belonging to the “Net Red” product.
On June 10, Jingdong responded that the eye drops banned in Canada are in compliance with local Japanese standards, and the standards applicable to the products on the global platform of Haishu are subject to the production area.
Despite this, Japan’s Shentian Pharmaceutical Co., Ltd., a manufacturer of eye drops, has also been pushed to the forefront of public opinion.
The four eye drops named “named” are FX Neo (black and silver packaging), FX Neo (color packaging), FX V+ and FX PC. These four products also include neostigmine methyl sulphate, FX Neo (black and silver packaging), FX Neo (color packaging), FX V + three products also contain aminocaproic acid.
According to the news report, neostigmine methyl sulphate is an anticholinergic drug that can shrink the pupillary effect, so it can bring a sense of use. However, this component may cause blurred vision, frontal lobe headache, eyelid twitching, red eye, cataract, iris cyst, retinal detachment, and induction of certain types of glaucoma, which may cause severe heart and respiratory side effects once inhaled through the lacrimal duct.
Another component, aminocaproic acid, helps to eliminate red blood cells when used in the eye. However, this component may be absorbed into the blood through the lacrimal duct, and may form a thrombus after accumulation to a certain amount, accompanied by side effects such as tearing, vision changes, headache, dizziness, nausea, muscle weakness, and rash.
The products are hot, most of them have side effects.
According to the official website of the State Food and Drug Administration, the four eye drops products that were banned in Canada have not obtained the Imported Drug Registration Certificate. According to China’s drug administration regulations, drugs that have not been approved for import are all treated as counterfeit drugs, and it is illegal to sell drugs that have not been approved for import.
In fact, the products produced by the company and sold in the Japanese market are popular among Chinese consumers.
According to the Nikkei Chinese Network, during the Spring Festival of 2018, another eye drop of Shentian Pharmaceuticals, “Sante Beautéye”, was ranked in the list of duty-free consumption of Tomod’s, a famous drugstore chain in Tokyo, Japan. fourth.
According to data provided by Baidu Japan, among the top six in the list of Japanese hot search shopping products (eye drops search index) from July to December 2018, only Le Dun’s small safflower eye drops ranked third, and the remaining five products All are produced by Shentian Pharmaceutical.
On the social platform, there are also many users who share the experience of using the article, which can effectively alleviate fatigue.
However, according to the list of products displayed by the Japanese official website of the company, there are 17 products in the company that contain at least one of the above-mentioned ingredients, and only 8 products are “survived”.
The profit is falling, the cost of sales is three times the cost of research and development.
According to the official website, Shentian Pharmaceutical is the leading company in the ophthalmic prescription drug market in Japan. It has a history of nearly 130 years and is sold to more than 60 countries.
According to previous media reports, in Japan, towering ophthalmic prescription drugs accounted for nearly half of the Japanese market, ranking first in Japan, and non-prescription eye drops are second only to Le Dun. In China, Shentian Pharmaceutical’s synthetic antibacterial eye drops have a market share of 35% in Chinese hospitals.
According to the financial report, the total revenue of Shentian Pharmaceutical in FY18 was 234.206 billion yen, a year-on-year increase of 4.0%, and the net profit was 31.943 billion yen, down 9.4% year-on-year. Among them, the cost of sales, general expenses and administrative expenses were 71.273 billion yen, while the cost of research and development expenditure was only 23.759 billion yen, about one-third of the former.
In terms of revenue distribution, the Asian market surpassed the EMEA (Europe, Middle East, Africa) market in FY18, becoming the second largest market after Japan, and its revenue growth rate in the Japanese market was only 1.14%. In Asia and the United States, the market is 19.35% and 43.67%, respectively, but the US market revenue is only about one-sixth of the Asian market.
At present, there are 11 kinds of medicines imported from Japan’s Shentian Pharmaceutical Co., Ltd. and registered on the website of the State Food and Drug Administration, mainly eye drops containing levofloxacin, ofloxacin, sodium hyaluronate, vitamin B12 or eye ointment, which is a common ophthalmology. drug. There is also a pirenoxine eye drop for the treatment of senile cataract. None of the above two drugs that may have side effects are included in all registered drugs.